Amide-Linked EP4 Agonist-Bisphosphonate Conjugates for Bone Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EP4 agonists used for treating bone-related conditions often have systemic side effects due to their non-specific delivery and action, and existing bisphosphonates may not effectively target bone sites for localized treatment.
Innovation Solution
Development of conjugate compounds that link an EP4 agonist with a bisphosphonate through an amide linker, allowing for targeted delivery to bone sites via an ester and amide bond, which can be hydrolyzed in vivo to release the active agent, reducing systemic side effects and enhancing bone-specific action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EP4 agonists are used for treating bone-related conditions, then bone formation is stimulated and bone mass increases, but systemic side effects occur due to non-specific delivery
Solution Approach 1:
The patent applies local quality by creating a conjugate compound where the EP4 agonist is specifically targeted to bone tissue through the bisphosphonate moiety. The bisphosphonate component binds selectively to hydroxyapatite in bone, ensuring the EP4 agonist is delivered locally to bone sites rather than systemically, thereby maintaining therapeutic efficacy while reducing off-target side effects.
Solution Approach 2:
The patent uses an amide linker as an intermediary component that connects the EP4 agonist to the bisphosphonate. This linker serves as a mediator that allows the conjugate to function as a unified targeting vehicle, where the bisphosphonate directs the complex to bone tissue and the linker maintains the structural integrity needed for effective delivery.
2Ease of operation
If existing bisphosphonates are used for bone targeting, then bone sites are targeted, but they do not effectively deliver EP4 agonist for localized treatment
Solution Approach 1:
The patent merges two distinct functional components into a single conjugate compound: the bone-targeting bisphosphonate and the therapeutic EP4 agonist. This combination allows the molecule to simultaneously achieve specific bone localization and deliver the therapeutic agent needed to stimulate bone formation, thereby enhancing both targeting capability and therapeutic efficacy.
3Reliability
If conjugate compounds are designed with amide linkers for targeted delivery, then bone-specific action is enhanced, but compound complexity increases
Solution Approach 1:
The patent employs composite material principles by creating a conjugate compound that integrates the EP4 agonist and bisphosphonate through an amide linker. This composite structure combines the bone-targeting properties of bisphosphonates with the bone-forming stimulation of EP4 agonists, achieving enhanced bone-specific action while the modular design allows for systematic optimization of the linkage components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate compounds achieve efficient uptake and retention at bone sites, reducing systemic side effects and improving the therapeutic efficacy for bone-related conditions by localized delivery and controlled release of the EP4 agonist.
Implementation Method 1
an ester and amide bond, which can be hydrolyzed in vivo to release the active agent
Data Source
AI summary
The present invention relates to EP4 agonist-bisphosphonate conjugates or related compounds and uses thereof. Said conjugates or related compounds may be used to provide delivery of an EP4 agonist or related compound to a desired site of action, such as a bone. Bisphosphonate moieties, linked to the EP4 agonists via amide linkers, have been implicated in the inhibition of bone resorption and bone targeting.